...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Wikipedia on Investor Relations: Goal is Fair Valuation

fouremm,,,,,,,,,,,,,,,,you are not far off probably,,,,,,,,,,,,I am trying to get my head around the delicate balance between KD and the RVX dream team,,,,,,,,,,I assume that KD wants as many ZEL shares as he can get his mitts on at a reasonable cost,,,,,,a third party PP in ZEL,,well if this was realistic to believe then it would or should or could provide DM leverage around that RVX LoC in 2017 perhaps to our favour,,,but that didnt happen!,,,that is for KD to remove the transfer of the IP in that previous PP agreement with RVX ,,,anything would be an improvement.....,were there really other offers/options out there on a PP in ZEL???,,,,,Banksters perhaps,,,,did DM try to work his majic with these outsiders?,,,,if so they must have had much weaker offers as we went back to KDs' man purse. I just get the feeling that KD has enuff clout within this epigenetic research saga now that DM is not given much berth in directing the company moves. We were in limbo for the past three years,,, like cicadas,,,,,time to get a few irons in the fire,,,I do hold onto the idea that ZEL will be in some sort of discovery mode well prior to BoM results,,just in case,,,,something to fall back on,,you know,,,no one will be out of a job so to speak,,,,not in our life time,,,just my opinion,,,,,,,

Share
New Message
Please login to post a reply